about
Common genetic variation and the control of HIV-1 in humansClinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 cell count > 350 × 106/lTiming of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studiesCost-effectiveness of genotypic antiretroviral resistance testing in HIV-infected patients with treatment failurePublic-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland comparedInflammatory and coagulation biomarkers and mortality in patients with HIV infectionDifferent patterns of inappropriate antimicrobial use in surgical and medical units at a tertiary care hospital in Switzerland: a prevalence surveyInflammation, coagulation and cardiovascular disease in HIV-infected individualsLong-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimensA Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected PatientsRibavirin Concentrations Do Not Predict Sustained Virological Response in HIV/HCV-Coinfected Patients Treated with Ribavirin and Pegylated Interferon in the Swiss HIV Cohort StudyFrequency of and Risk Factors for Depression among Participants in the Swiss HIV Cohort Study (SHCS)Factors Associated with Low-Level Viraemia and Virological Failure: Results from the Austrian HIV Cohort StudyCorrection: Long-Lasting Protection of Activity of Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors (PIs) by Boosted PI Containing RegimensMinor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patients
P50
Q21092450-2BBFDFB9-1112-449E-B26C-3291DB290036Q21128672-A8DB828B-9629-47FD-B0F7-98969E7E663BQ24656950-AFAB5B63-9361-4EC2-B86F-5864426BE7FEQ28469116-EB7E4007-84FF-4492-87AB-F4EB76A47BE1Q28473120-6074C558-946A-4714-85AC-28011B8CC4ECQ28473903-A10C9A13-D168-4EB6-B547-EBFEC9926ACCQ28476167-1CBF5B67-A277-4037-9338-93633820B46AQ28483645-B5C3F8B6-4DEF-47C5-A5D2-25F48CE06242Q28485321-97325199-01B6-452C-8669-B8E9767C530AQ28546535-7BA13C7F-A8EF-4D61-B4C3-9886D93FFAB7Q28546829-160074BA-4A29-4624-A7B6-D34B36E26E2FQ28550440-A274EE16-3B6A-414D-9538-321FC1435735Q28550940-F3B97C4E-C970-4F1D-B9D5-F41356CF7A92Q28683189-C785F9DC-79BD-4ADC-BB19-3598899824A4Q28728304-C4CB793D-C53E-4700-B79E-10B8C4C75D7E
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Bruno Ledergerber
@ast
Bruno Ledergerber
@en
Bruno Ledergerber
@es
Bruno Ledergerber
@fr
Bruno Ledergerber
@nl
Bruno Ledergerber
@sl
type
label
Bruno Ledergerber
@ast
Bruno Ledergerber
@en
Bruno Ledergerber
@es
Bruno Ledergerber
@fr
Bruno Ledergerber
@nl
Bruno Ledergerber
@sl
prefLabel
Bruno Ledergerber
@ast
Bruno Ledergerber
@en
Bruno Ledergerber
@es
Bruno Ledergerber
@fr
Bruno Ledergerber
@nl
Bruno Ledergerber
@sl
P1053
B-5656-2009
P106
P21
P31
P3829
P496
0000-0002-6881-4401
P569
2000-01-01T00:00:00Z